Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 16, 2007

Perlegen to Develop a Breast Cancer Test

  • Perlegen Sciences obtained an exclusive commercial license from University of Cambridge to certain breast cancer markers. The company plans to commercialize a diagnostic test, either directly or through a sublicense agreement with a third party.

    The markers were identified through research conducted by the university, Cancer Research Technology (CRT), and Cancer Research U.K. The study, published in the June issue of Nature, identified novel breast cancer susceptibility markers that are present in approximately 20% of U.K. breast cancer cases. 

    University of Cambridge and CRT will share in any financial returns from the diagnostic product. In addition, University of Cambridge may provide noncommercial licenses to academic researchers.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »